NASDAQ:RVPH

Reviva Pharmaceuticals (RVPH) Stock Forecast, Price & News

$6.78

+0.33 (+5.12%)

(As of 06/2/2023 ET)

Compare

Today's Range: $6.31
▼
$6.92
50-Day Range: $3.93
▼
$8.55
52-Week Range: $0.53
▼
$9.25

Volume: 180,873 shs
Average Volume: 148,407 shs
Market Capitalization: $138.65 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $18.00

Reviva Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 165.5% Upside
$18.00 Price Target
Short Interest: Bearish
7.97% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.01) to ($0.84) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.49 out of 5 stars

Medical Sector

834th out of 983 stocks

Pharmaceutical Preparations Industry

418th out of 486 stocks

3.5

Analyst's Opinion

Consensus Rating
Reviva Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $18.00, Reviva Pharmaceuticals has a forecasted upside of 165.5% from its current price of $6.78.
Amount of Analyst Coverage
Reviva Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

0.0

Short Interest

Percentage of Shares Shorted
7.97% of the outstanding shares of Reviva Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Reviva Pharmaceuticals has a short interest ratio ("days to cover") of 10.8, which indicates bearish sentiment.
Change versus previous month
Short interest in Reviva Pharmaceuticals has recently increased by 20.74%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Reviva Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Reviva Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RVPH.

0.0

News and Social Media Coverage

Search Interest
Only 14 people have searched for RVPH on MarketBeat in the last 30 days. This is a decrease of -26% compared to the previous 30 days.
MarketBeat Follows
Only 2 people have added Reviva Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Reviva Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
32.06% of the stock of Reviva Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 10.29% of the stock of Reviva Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Reviva Pharmaceuticals are expected to grow in the coming year, from ($1.01) to ($0.84) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Reviva Pharmaceuticals is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Reviva Pharmaceuticals is -5.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Reviva Pharmaceuticals has a P/B Ratio of 24.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Reviva Pharmaceuticals (NASDAQ:RVPH) Stock

Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Receive RVPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Reviva Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

RVPH Stock News Headlines

May 25, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Announced Preclinical Efficacy Data on Brilaroxazine in IPF at the 2023 American Thoracic Society International Conference and Publication in Medical Research Archives

May 22, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Announces Presentation of Clinical Pharmacology Studies Data on Brilaroxazine at the ASPET 2023 Annual Meeting

June 2, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

May 19, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Joins Webull Corporate Communications Service Platform

May 18, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to Present at Upcoming Investor Conferences in May 2023

May 17, 2023 | finance.yahoo.com

RVPH: Psoriasis IND Expected

May 16, 2023 | finanznachrichten.de

Reviva Pharmaceuticals: Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

May 15, 2023 | finance.yahoo.com

Reviva Reports First Quarter 2023 Financial Results and Recent Business Highlights

June 2, 2023 | Behind the Markets (Ad)

"Unknown laser company making HUGE profit from Russia-Ukraine War"

On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>

May 12, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference

May 11, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Announces Intent to File an IND for Brilaroxazine in Psoriasis After Promising Preclinical Data

May 5, 2023 | americanbankingnews.com

Reviva Pharmaceuticals (NASDAQ:RVPH) PT Raised to $18.00

May 4, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to Present at Three Upcoming Scientific Conferences in May 2023

May 3, 2023 | msn.com

Maxim Group Maintains Reviva Pharmaceuticals Holdings (RVPH) Buy Recommendation

May 1, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Presented Foundational Preclinical Data on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual SOBP and Publication in Medical Research Archives

April 21, 2023 | msn.com

Unusual Call Option Trade in Reviva Pharmaceuticals Holdings (RVPH) Worth $30.00K

April 20, 2023 | finance.yahoo.com

Reviva Pharmaceuticals to Present on Novel Serotonin-Dopamine Stabilizer Brilaroxazine at the 78th Annual Scientific Convention of the Society of Biological Psychiatry

April 8, 2023 | americanbankingnews.com

FY2023 EPS Estimates for Reviva Pharmaceuticals Holdings, Inc. Decreased by Analyst (NASDAQ:RVPH)

April 8, 2023 | americanbankingnews.com

Reviva Pharmaceuticals Holdings, Inc. Forecasted to Post Q1 2023 Earnings of ($0.36) Per Share (NASDAQ:RVPH)

April 6, 2023 | americanbankingnews.com

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Rating Reaffirmed by HC Wainwright

April 5, 2023 | americanbankingnews.com

Research Analysts Set Expectations for Reviva Pharmaceuticals Holdings, Inc.'s Q1 2024 Earnings (NASDAQ:RVPH)

April 4, 2023 | msn.com

HC Wainwright & Co. Reiterates Reviva Pharmaceuticals Holdings (RVPH) Buy Recommendation

April 4, 2023 | finance.yahoo.com

RVPH: RECOVER Parallel Studies Complete

April 1, 2023 | markets.businessinsider.com

Reviva Pharmaceuticals Holdings (RVPH) Receives a Buy from Maxim Group

March 30, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights

March 30, 2023 | finance.yahoo.com

Reviva Pharmaceuticals Holdings, Inc. Reports Full Year 2022 Financial Results and Recent Business Highlights

March 10, 2023 | finance.yahoo.com

RVPH: Brilaroxazine Enthusiasm Abounds

See More Headlines

RVPH Price History

30 days | 90 days | 365 days | Advanced Chart

RVPH Company Calendar

Last Earnings: 11/15/2021
Today: 6/02/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RVPH
CUSIP: N/A
CIK: 1742927
Web: www.revivapharma.com
Phone: (408) 501-8881
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $18.00
High Stock Price Forecast: $20.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +179.1%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.15)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-24,340,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -172.98%
Return on Assets: -123.26%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 1.97
Quick Ratio: 1.97

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.28 per share
Price / Book: 23.04

Miscellaneous

Outstanding Shares: 20,450,000
Free Float: 13,895,000
Market Cap: $131.90 million
Optionable: Not Optionable
Beta: 0.13

Key Executives

Laxminarayan Bhat
President, Chief Executive Officer & Director

Narayan Prabhu
Chief Financial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RVPH Stock - Frequently Asked Questions

Should I buy or sell Reviva Pharmaceuticals stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Reviva Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" RVPH shares.
View RVPH analyst ratings or view top-rated stocks.
What is Reviva Pharmaceuticals' stock price forecast for 2023?: 3 equities research analysts have issued 12-month price targets for Reviva Pharmaceuticals' shares. Their RVPH share price forecasts range from $16.00 to $20.00. On average, they anticipate the company's stock price to reach $18.00 in the next year. This suggests a possible upside of 179.1% from the stock's current price.
View analysts price targets for RVPH or view top-rated stocks among Wall Street analysts.
How have RVPH shares performed in 2023?: Reviva Pharmaceuticals' stock was trading at $4.25 at the beginning of the year. Since then, RVPH shares have increased by 51.8% and is now trading at $6.45.
View the best growth stocks for 2023 here.
Are investors shorting Reviva Pharmaceuticals?: Reviva Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 1,630,000 shares, an increase of 20.7% from the April 30th total of 1,350,000 shares. Based on an average trading volume of 150,600 shares, the short-interest ratio is currently 10.8 days.
View Reviva Pharmaceuticals' Short Interest.
When is Reviva Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our RVPH earnings forecast.
How were Reviva Pharmaceuticals' earnings last quarter?: Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) announced its earnings results on Monday, November, 15th. The company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.11.

What is Reviva Pharmaceuticals' stock symbol?: Reviva Pharmaceuticals trades on the NASDAQ under the ticker symbol "RVPH."
Who are Reviva Pharmaceuticals' major shareholders?: Reviva Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Susquehanna International Group LLP (0.00%), Colony Group LLC (0.45%), Two Sigma Investments LP (0.08%), Belvedere Trading LLC (0.00%), Group One Trading L.P. (0.00%) and Sabby Management LLC (0.00%). Insiders that own company stock include Prabhu Narayan, Purav Patel and Vedanta Partners, Llc.
View institutional ownership trends.
How do I buy shares of Reviva Pharmaceuticals?: Shares of RVPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Reviva Pharmaceuticals' stock price today?: One share of RVPH stock can currently be purchased for approximately $6.45.
How much money does Reviva Pharmaceuticals make?: Reviva Pharmaceuticals (NASDAQ:RVPH) has a market capitalization of $131.90 million. The company earns $-24,340,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis.
How can I contact Reviva Pharmaceuticals?: Reviva Pharmaceuticals' mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The official website for the company is www.revivapharma.com. The company can be reached via phone at (408) 501-8881 or via email at ir.revivapharma.com.

This page (NASDAQ:RVPH) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial